The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | ROP-ET: a Phase III non-randomized study of ropeginterferon alfa-2b in patients with ET
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, introduces the ROP-ET study (EudraCT, 2023-505160-12-00), a Phase III non-randomized trial which will investigate the use of ropeginterferon alfa-2b for the treatment of patients with essential thrombocythemia (ET). Prof. Kiladjian hopes this agent will provide a novel therapeutic option for patients with ET who become resistant to all currently available treatments. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
